In the first instance, we assessed whether reversion mutations in BRCA1, the most clinically validated mechanism of PARPi and platinum salt resistance in BRCA1 mutant cancers [10], could explain the PARPi resistance in this individual. This evidence concerns the gene BRCA1 and cancer.